ArticleMolecular pharmaceutics2012
Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer.
Article in Molecular pharmaceutics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 86 citations in OpenAlex.
- RNA Regulatory Networks: Key Hubs in the Panorama of Cancer and Emerging Therapeutic Targets.MedComm · 2026Review
- Non-Viral RNA Therapies for Non-Small Cell Lung Cancer and Their Corresponding Clinical Trials.Molecular pharmaceutics · 2025Review
- Programming assembly of biomimetic exosomes: An emerging theranostic nanomedicine platform.Materials today. Bio · 2023Review
- The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses.International journal of molecular sciences · 2023Review
- Exosomal targeting and its potential clinical application.Drug delivery and translational research · 2022Review
- Nanomedicine for the Delivery of RNA in Cancer.Cancers · 2022Review
- Novel Pyropheophorbide Phosphatydic Acids Photosensitizer Combined EGFR siRNA Gene Therapy for Head and Neck Cancer Treatment.Pharmaceutics · 2021Article
- Application of Nanoparticles in the Treatment of Lung Cancer With Emphasis on Receptors.Frontiers in pharmacology · 2021Review
- Anti-Biomedicines · 2020Review
- Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.Drug delivery · 2020Article
- Cancer-Targeting Nanoparticles for Combinatorial Nucleic Acid Delivery.Advanced materials (Deerfield Beach, Fla.) · 2020Review
- Fabrication and Characterization of Calcium-Phosphate Lipid System for Potential Dental Application.Frontiers in chemistry · 2020Article
- mRNA Vaccine with Antigen-Specific Checkpoint Blockade Induces an Enhanced Immune Response against Established Melanoma.Molecular therapy : the journal of the American Society of Gene Therapy · 2018Article
- Nanoformulations for combination or cascade anticancer therapy.Advanced drug delivery reviews · 2017Review
- Targeted Delivery of siRNA Therapeutics to Malignant Tumors.Journal of drug delivery · 2017Review
- Cancer nanomedicine: progress, challenges and opportunities.Nature reviews. Cancer · 2017Review
- Delivery strategies and potential targets for siRNA in major cancer types.Advanced drug delivery reviews · 2016Review
- Lipid Nanovectors to Deliver RNA Oligonucleotides in Cancer.Nanomaterials (Basel, Switzerland) · 2016Review
- Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.Cancer treatment reviews · 2016Review
- Gold Nanosphere Gated Mesoporous Silica Nanoparticle Responsive to Near-Infrared Light and Redox Potential as a Theranostic Platform for Cancer Therapy.Journal of biomedical nanotechnology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related death. To explore the potential of small interfering RNA (siRNA) therapy for NSCLC, we have developed anisamide-targeted LCP to efficiently deliver siRNA into the cytoplasm of sigma receptor-expressing NSCLC cells. Targeted LCP demonstrated a 9-fold higher siRNA delivery efficiency compared to nontargeted LCP in A549 cells in vitro. To simultaneously target multiple oncogenic mechanisms, we coformulated three siRNA sequences targeting HDM2, c-myc and VEGF oncogenes, and investigated their efficacy of cell-killing in A549 and H460 cells in vitro. The results indicated that the pooled siRNA codelivered by the targeted LCP could effectively and simultaneously knock down HDM2, c-myc and VEGF expressions and significantly inhibit tumor cell growth. After iv injection of mice bearing A549 xenografted tumor with Texas Red-labeled siRNA formulated in the targeted LCP, siRNA was successfully delivered to and concentrated in the tumor cells. Repeated intravenous injections of mice with pooled siRNA formulated in the targeted LCP significantly impaired NSCLC growth in vivo (p < 0.01) for both A549 and H460 tumors, demonstrating an ED50 for the treatment of ∼ 0.2 mg/kg in A549 tumors. The enhanced antitumor activity is due to the fact that the silencing of HDM2/c-myc/VEGF could inhibit tumor proliferation and angiogenesis and also simultaneously induce tumor apoptosis. Our results demonstrate that the targeted LCP is a promising vector to deliver pooled siRNA into tumors and to achieve multiple target blocking. This is potentially a valid therapeutic modality in the gene therapy of human NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.